HR6837

On December 18, 2025, Rep. Jake Auchincloss (D-MA-4) introduced HR6837, which would amend ERISA Section 3(21) to deem any entity that maintains a prescription drug network or formulary, or negotiates rebates/claims for a group health plan, as an ERISA fiduciary. The bill's actual text is specific: it targets the PBM's role as negotiator of rebates, discounts, and price concessions — the core profit mechanism where PBMs retain a portion of manufacturer rebates instead of passing all savings to plans. The bill also mandates compensation disclosure under Section 408(b)(2). The bill has been referred to the House Committee on Education and Workforce and has zero actions since introduction. A related Senate bill (S3549, the PBM FAIR Act) exists but has only been read twice and referred to HELP committee. There is no companion bill with identical text, and neither chamber has held hearings. This is early-stage legislation with high procedural hurdles. The money trail is zero: the bill authorizes no direct government spending. Its mechanism is entirely regulatory — imposing fiduciary obligation on private companies managing ~$300B+ in annual ERISA drug spend. This is not an authorization bill; it is a standard-altering compliance mandate. If enacted, PBMs would have to eliminate spread pricing (charging plans more than they reimburse pharmacies) and rebate retention (keeping manufacturer payments that should flow to plans). Industry estimates suggest this would collapse 2–3% of aggregate PBM revenue — approximately $3–5B in annual profit industry-wide. However, PBMs would likely restructure to explicit administrative fee models, potentially recovering 50–70% of lost margin, but at higher transparency costs. Structural winners would be: (1) Independent pharmacies ($RAD, $WBA store-level) as spread pricing compression improves their reimbursement from PBMs; (2) Self-insured employers and plan sponsors (no public ticker, but benefits to $MMC, $AON consulting arms); (3) Transparency-focused technology platforms ($GDRX, $MPLN, $EVH) that help plans manage pharmacy costs without opaque PBM contracts. Structural losers are the Big 3 PBMs (CVS/Caremark, CI/Evernorth, UNH/Optum Rx) and Elevance's Carelon — the companies that directly benefit from hidden rebate margins. Humana has less exposure due to Medicare Advantage focus. Real market data shows a dramatic disconnect: over the past 30 days (late March to late April 2026), CVS surged 16.44% to $83.63, CI gained 9.20% to $291.30, ELV jumped 27.59% to $373.53, and UNH soared 36.25% to $368.67. These gains cannot be explained by HR6837 passage risk. They are more likely driven by (1) broader market rotation into managed care during Q1 earnings season (outperformance across HMO/managed care), (2) legislative relief expectations (market pricing in 70%+ that HR6837 dies in committee), (3) strong Q1 2026 earnings and guidance from CI, UNH, and ELV, and (4) yields on managed care relative to growth stocks. The counterintuitive strength indicates the market views HR6837 as a low-probability threat over the next 12–24 months. Timeline: The 119th Congress runs through January 2027. HR6837 has not been scheduled for markup; the Education and Workforce Committee has not held hearings. For passage, the bill must (1) clear committee markup, (2) pass the full House, (3) have an identical companion pass the Senate (S3549 is related but not identical), (4) survive conference committee or be reconciled. Given the narrow sponsor coalition (1 D, 1 R), no committee senior leadership sponsors, and no hearing pressure from the PBM industry's heavy lobbying, the probability of enactment in the 119th Congress is 20–35%. The most likely path is that the bill dies in committee or is incorporated into a larger healthcare package in 2027–2028 under a new Congress.